M2RLAB, S.L.
Primary tabs
About your organization / profile
M2RLAB IS A BIOTECH COMPANY WHERE WE HAVE DEVELOPED A BREAKTHROUGH CELL THERAPY TO CURE ACUTE FIBROTIC DESEASES, AND ACUTE KIDNEY INJURY IS OUR FIRST TARGET.
WE DO OUR RESEARCH FROM TWO LAB FACILITIES LOCATED AT TOP PUBLIC RESEARCH INSTITUTES IN BARCELONA AND MADRID. AND WE ALSO HAVE OPENED A CENTRALIZED PRODUCTION FACILITY FOR OUR CELL THERAPY TO SERVE A WIDE GEOGRAPHICAL AREA AS PART AS OUR CLINICAL PROGRAM TO TREAT AKI. WE ARE PRESENTING A PHASE II CLINICAL TRIAL FOR 120 PATIENTS IN Q1 2024.
OUR TECHNOLOGY IS SIMPLE TO MANUFACTURE, SCALABLE AND IS PROTECTED BY PATENTS IN THE EU, USA, JAPAN AND 5 OTHER MARKETS. IN ADDITION TO KIDNEY INJURY WE HAVE PRECLINICAL APPLICATIONS FOR ARDS, LUPUS NEPHRITIS AND TENDON INJURY.
YOU CAN CHECK MORE AT WWW.M2RLAB.COM
Recent activities
M2RLAB, S.L. is now a member of the EIC ACCESS+ community.
M2RLAB, S.L. has been awarded the FUNDACIÓN PARA EL CONOCIMIENTO MADRI+D label.
M2RLAB, S.L. has joined the WOMEN ANGELS FOR STEAM network.
M2RLAB, S.L. has joined the Supernova Invest network.
The dataroom has been updated.
M2RLAB, S.L. is now a member of the EEN2EIC - Seal of Excellence community.
The dataroom has been updated.
Pablo García de la Riva Mestre has joined M2RLAB, S.L..
Pablo Garcia de la Riva has joined M2RLAB, S.L..